297 related articles for article (PubMed ID: 18279044)
1. Mild-to-moderate symptoms during the first year of antiretroviral therapy worsen quality of life in HIV-infected individuals.
Mannheimer SB; Wold N; Gardner EM; Telzak EE; Huppler Hullsiek K; Chesney M; Wu AW; MacArthur RD; Matts J; Friedland G;
Clin Infect Dis; 2008 Mar; 46(6):941-5. PubMed ID: 18279044
[TBL] [Abstract][Full Text] [Related]
2. Effect of lopinavir/ritonavir monotherapy on quality of life and self-reported symptoms among antiretroviral-naive patients: results of the MONARK trial.
Spire B; Marcellin F; Cohen-Codar I; Flandre P; Boue F; Dellamonica P; Raffi F; Norton M; Van Philippe N; Delfraissy JF
Antivir Ther; 2008; 13(4):591-9. PubMed ID: 18672538
[TBL] [Abstract][Full Text] [Related]
3. Rapid decay of HIV RNA in the cerebrospinal fluid during antiretroviral combination therapy.
Stellbrink HJ; Eggers C; van Lunzen J; Albrecht H; Greten H
AIDS; 1997 Nov; 11(13):1655-7. PubMed ID: 9365775
[No Abstract] [Full Text] [Related]
4. Virological failure and adherence to antiretroviral therapy in HIV-infected patients.
Rodríguez-Rosado R; Jiménez-Nácher I; Soriano V; Antón P; González-Lahoz J
AIDS; 1998 Jun; 12(9):1112-3. PubMed ID: 9662214
[No Abstract] [Full Text] [Related]
5. Current HIV therapeutics: mechanistic and chemical determinants of toxicity.
Chiao SK; Romero DL; Johnson DE
Curr Opin Drug Discov Devel; 2009 Jan; 12(1):53-60. PubMed ID: 19152213
[TBL] [Abstract][Full Text] [Related]
6. Effect of the substitution of one nucleoside analogue by one non-nucleoside reverse transcriptase inhibitor over mitochondrial DNA levels.
De Felipe B; Blanco A; Soriano-Sarabia N; Muñoz-Fernández MA; Genebat M; Vallejo A; Leal M
Infection; 2008 Jun; 36(3):266-70. PubMed ID: 18463785
[TBL] [Abstract][Full Text] [Related]
7. Guidelines for use of antiretroviral therapy for HIV infected individuals in India (ART guidelines 2008).
Pujari S; Patel A; Joshi SR; Gangakhedkar R; Kumarasamy N; Gupta SB;
J Assoc Physicians India; 2008 May; 56():339-48, 353-71. PubMed ID: 18700643
[No Abstract] [Full Text] [Related]
8. The year in review: antiretroviral treatment.
Hirschel B; Opravil M
AIDS; 1999; 13 Suppl A():S177-87. PubMed ID: 10885775
[No Abstract] [Full Text] [Related]
9. Virologic and immunologic responses to antiretroviral therapy among HIV-1 and HIV-2 dually infected patients: case reports from Abidjan, Côte d'Ivoire.
Borget MY; Diallo K; Adje-Toure C; Chorba T; Nkengasong JN
J Clin Virol; 2009 May; 45(1):72-5. PubMed ID: 19375979
[TBL] [Abstract][Full Text] [Related]
10. Protease inhibitors and mortality among children and adolescents infected with HIV-1.
Barbaro G
N Engl J Med; 2002 Mar; 346(13):1026-7; author reply 1026-7. PubMed ID: 11919316
[No Abstract] [Full Text] [Related]
11. The current role of ritonavir-boosted protease inhibitors in the management of HIV infection.
Wilkins E
J HIV Ther; 2008 Mar; 13(1):9-18. PubMed ID: 18953268
[No Abstract] [Full Text] [Related]
12. Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.
Landman R; Capitant C; Descamps D; Chazallon C; Peytavin G; Katlama C; Pialoux G; Bentata M; Brun-Vézinet F; Aboulker JP; Yéni P;
J Antimicrob Chemother; 2009 Jul; 64(1):118-25. PubMed ID: 19420019
[TBL] [Abstract][Full Text] [Related]
13. New antiretroviral tactics: transitions or mere trends? An interview with Joep Lange,MD,PhD. Interview by Mark Mascolini.
Mascolini M
J Int Assoc Physicians AIDS Care; 1999 Jul; 5(7):25-9. PubMed ID: 11367133
[TBL] [Abstract][Full Text] [Related]
14. Second-line antiretroviral therapy in resource-limited settings: the experience of Médecins Sans Frontières.
Pujades-Rodríguez M; O'Brien D; Humblet P; Calmy A
AIDS; 2008 Jul; 22(11):1305-12. PubMed ID: 18580610
[TBL] [Abstract][Full Text] [Related]
15. Antiretroviral therapy with or without protease inhibitors impairs postprandial TAG hydrolysis in HIV-infected men.
Ware LJ; Jackson AG; Wootton SA; Burdge GC; Morlese JF; Moyle GJ; Jackson AA; Gazzard BG
Br J Nutr; 2009 Oct; 102(7):1038-46. PubMed ID: 19480729
[TBL] [Abstract][Full Text] [Related]
16. HIV therapeutics: past, present, and future.
Abu-ata O; Slim J; Perez G; Smith SM
Adv Pharmacol; 2000; 49():1-40. PubMed ID: 11013759
[No Abstract] [Full Text] [Related]
17. Nucleoside reverse transcriptase inhibitor-sparing regimen (nonnucleoside reverse transcriptase inhibitor + protease inhibitor) was more likely associated with resistance comparing to nonnucleoside reverse transcriptase inhibitor or protease inhibitor + nucleoside reverse transcriptase inhibitor in the randomized ANRS 121 trial.
Soulié C; Assoumou L; Ghosn J; Duvivier C; Peytavin G; Ait-Arkoub Z; Molina JM; Costagliola D; Katlama C; Calvez V; Marcelin AG
AIDS; 2009 Jul; 23(12):1605-8. PubMed ID: 19487903
[TBL] [Abstract][Full Text] [Related]
18. Nucleoside analogues in 2008.
Warwick Z; Churchill D
J HIV Ther; 2008 Mar; 13(1):3-8. PubMed ID: 18953267
[No Abstract] [Full Text] [Related]
19. Profile of drug resistance mutations among HIV-1-infected Tunisian subjects failing antiretroviral therapy.
Jlizi A; Ben Ammar El Gaaied A; Slim A; Tebourski F; Ben Mamou M; Ben Chaabane T; Letaief-Omezzine A; Chakroun M; Garbouj M; Ben Rejeb S
Arch Virol; 2008; 153(6):1103-8. PubMed ID: 18483694
[TBL] [Abstract][Full Text] [Related]
20. Primary drug resistance in antiretroviral-naïve injection drug users.
Tossonian HK; Raffa JD; Grebely J; Viljoen M; Mead A; Khara M; McLean M; Krishnamurthy A; DeVlaming S; Conway B
Int J Infect Dis; 2009 Sep; 13(5):577-83. PubMed ID: 19111493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
